In February of 2018, the Personalized Medicine Coalition (PMC), a 501(c)3 educational and advocacy organization, published Personalized Medicine at FDA: 2017 Progress Report to underline the record number of 19 personalized medicines the U.S. Food and Drug Administration (FDA) approved in 2017, demonstrating the significance of continued progress in developing personalized treatments and, equally important, the diagnostics upon which they depend.
The report reminds us of why PMC exists.
In accordance with its mission to promote the understanding and adoption of personalized medicine concepts, services and products on behalf of more than 200 institutional members from every sector of the health system, PMC shares these kinds of materials with thought leaders from Congress, FDA, the Centers for Medicare and Medicaid Services (CMS), and the private sector. We seek, in particular, to shape regulatory policies that facilitate the efficient approval of personalized medicine products; to generate evidence and champion policy reforms to support an improved reimbursement environment for personalized medicine products and services; and to influence provider practices to accelerate the pace at which personalized medicine is integrated in the clinic.
Suffice it to say, we hope you will invest in the success of our work by becoming a member of the Coalition because, as we know, the paradigm shift away from a one-size-fits-all health care system and toward personalized medicine will not happen just because the science and new technologies suggest it should. Your support would go a long way toward ensuring that policies and practices in the public and private sectors pave the way for the field.
Please contact me at email@example.com or 202-589-0070 if you have any questions.
Director, Membership & Development